Cryo-Cell International, Inc.

NYSEAM:CCEL Stock Report

Market Cap: US$67.3m

Cryo-Cell International Valuation

Is CCEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CCEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CCEL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CCEL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CCEL?

Key metric: As CCEL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CCEL. This is calculated by dividing CCEL's market cap by their current revenue.
What is CCEL's PS Ratio?
PS Ratio2.1x
SalesUS$31.84m
Market CapUS$67.30m

Price to Sales Ratio vs Peers

How does CCEL's PS Ratio compare to its peers?

The above table shows the PS ratio for CCEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.8x
CDIX Cardiff Lexington
13.1xn/aUS$98.9m
ME 23andMe Holding
0.4xn/aUS$80.4m
PIII P3 Health Partners
0.02x8.4%US$76.4m
LDDD Longduoduo
21.7xn/aUS$142.8m
CCEL Cryo-Cell International
2.1x1.0%US$67.3m

Price-To-Sales vs Peers: CCEL is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (8.8x).

Price to Sales Ratio vs Industry

How does CCEL's PS Ratio compare vs other companies in the US Healthcare Industry?

30 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$79.11b
CVS CVS Health
0.2x4.6%US$73.00b
COR Cencora
0.2x6.4%US$48.03b
CNC Centene
0.2x5.5%US$30.48b
CCEL 2.1xIndustry Avg. 1.1xNo. of Companies30PS012345+
30 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CCEL is expensive based on its Price-To-Sales Ratio (2.1x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is CCEL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CCEL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: CCEL is expensive based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.37

7D

5.1%

1Y

-18.8%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.9%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

2.5%

1Y

101.6%